Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Cellenkos, Inc. logo — Developing off-the-shelf T regulatory (Treg) cell therapies...

Cellenkos, Inc.

Developing off-the-shelf T regulatory (Treg) cell therapies for rare inflammatory diseases and autoimmune disorders.

Founded 2016 14 employees Series A Total: $15.00M Biotechnology

General Information

Company Name Cellenkos, Inc.
Founded Year 2016
Founders / Decision Makers
Team member
Employees 14
Industries Biotechnology
Funding Stage Series A
Business Model B2B, B2D
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Cellenkos, Inc.. To contact Cellenkos, Inc., visit cellenkosinc.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Cellenkos, Inc. compare?

A PDF of Cellenkos, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Cellenkos, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Cellenkos, Inc.

Cellenkos, Inc., established in 2016, is a clinical stage biotechnology company with a focus on developing off-the-shelf T regulatory (Treg) cell therapies for rare inflammatory and autoimmune diseases. Pioneered from a proprietary platform licensed from MD Anderson Cancer Center, Cellenkos leverages its CRANE® Platform for the selection and enrichment of umbilical cord blood-derived Tregs, offering specialized solutions across areas such as oncology and neurology.

Distinguished by the capability of manufacturing therapies that do not require HLA matching, these treatments can be rapidly produced and administered on an outpatient basis. The company operates within the Biotechnology industry, yet its geographical base remains unspecified.

On 04 November 2021, Cellenkos secured a $15.00M Series A investment, backed notably by BVCF. As Cellenkos progresses through its clinical stages, it presents a compelling proposition for investors seeking to capitalize on the burgeoning market of innovative immune-modulatory therapies.

Business keywords: Treg Cell Therapy, Allogeneic Products, Inflammatory Diseases, Autoimmune Disorders, CRANE Platform, Umbilical Cord Blood, Rare Autoimmune Blood Disorders, Cell Therapy, Immunomodulation, Oncology, Neuro-degenerative Diseases, Inflammatory Pulmonary Disease, MD Anderson Cancer Center, Clinical-Stage

Services & Products

Development of T-Regulatory Cell Therapies
Clinical Trial Management
Allogeneic Therapy Research

Target Customers

Patients with Autoimmune Diseases Healthcare Providers Biotechnology Researchers Pharmaceutical Companies

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $15.00M 1
BVCF
04 Nov 2021

Cellenkos, Inc. Alternatives & Competitors

View All Alternatives
Cellenkos, Inc. vs
Cell BioEngines, Inc
Cell BioEngines, Inc United States

‘Off-the-Shelf’ Curative Cell Therapies

Pre-Seed
3 employees
Biotechnology, Health and Wellness
Cellenkos, Inc. vs
Lineage Cell Therapeutics
Lineage Cell Therapeutics United States

A clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.

Post-IPO Equity
33 employees
Biopharma, Biotechnology
Cellenkos, Inc. vs
Celularity Inc.
Celularity Inc. United States

A next-gen Biotech company creating off-the-shelf cellular medicines for Cancer, Infectious, and Deg...

Post-IPO Equity
171 employees
Biotechnology, Health Care
Also compare with: Cellenkos, Inc. vs Sonoma Biotherapeutics, Inc. Sonoma Biotherapeutics, Inc. Cellenkos, Inc. vs Tr1X Tr1X View all alternatives

FAQ About Cellenkos, Inc.

Developing off-the-shelf T regulatory (Treg) cell therapies for rare inflammatory diseases and autoimmune disorders.
Cellenkos, Inc. was founded in 2016.
Cellenkos, Inc. operates in Biotechnology. Its work centres on Treg Cell Therapy, Allogeneic Products, Inflammatory Diseases and Autoimmune Disorders. Its customers include Patients with Autoimmune Diseases, Healthcare Providers and Biotechnology Researchers.
Cellenkos, Inc. has a B2B and B2D business model. Its revenue comes from Licensing and Product Sales.
Cellenkos, Inc. has approximately 14 employees.
Cellenkos, Inc. has completed 1 funding round, raising a total of $15.00M. The latest funding stage is Series A.
Cellenkos, Inc. offers: Development of T-Regulatory Cell Therapies, Clinical Trial Management, Allogeneic Therapy Research.
Top alternatives and competitors to Cellenkos, Inc. include Cell BioEngines, Inc, Lineage Cell Therapeutics, Celularity Inc., Tmunity Therapeutics, Mozart Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Cellenkos, Inc. and Cell BioEngines, Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Cellenkos, Inc., https://bouncewatch.com/company/cellenkos-inc, updated 2 April 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout